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Adam W. Beck, MD,a Gainesville, Fla; and Lebanon, NH
Background: Simultaneous treatment of multilevel aortic disease is controversial due to the theoretic increase in
morbidity. This study was conducted to define the outcomes in patients treated electively with simultaneous thoracic
endovascular aortic aneurysm repair (TEVAR) and abdominal aortic endovascular endografting for synchronous aortic
pathology.
Methods: Patients treated with simultaneous TEVAR and endovascular aneurysm repair (T&E) at the University of
Florida were identified from a prospectively maintained endovascular aortic registry and compared with those treated
with TEVAR alone (TA). The study excluded patients with urgent or emergency indications, thoracoabdominal or
mycotic aneurysm, and those requiring chimney stents, fenestrations, or visceral debranching procedures. Demographics,
anatomic characteristics, operative details, and periprocedural morbidity were recorded. Mortality and reintervention
were estimated using life-table analysis.
Results: From 2001 to 2011, 595 patients underwent TEVAR, of whom 457 had elective repair. Twenty-two (18 men,
82%) were identified who were treated electively with simultaneous T&E. Mean  standard deviation age was 66  9
years, and median follow-up was 8.8 months (range, 1-34 months). Operative indications for the procedure included
dissection-related pathology in 10 (45%) and various combinations of degenerative etiologies in 12 (55%). Compared
with TA, T&E patients had significantly higher blood loss (P< .0001), contrast exposure (P< .0001), fluoroscopy time
(P < .0001), and operative time (P < .0001). The temporary spinal cord ischemia rate was 13.6% (n  3) for the T&E
group and 6.0% for TA (P  .15); however, the permanent spinal cord ischemia rate was 4% for both groups (P  .96).
The 30-day mortality for T&E was 4.5% (n  1) compared with 2.1% (n  10) for TA. Temporary renal injury (defined
by a 25% increase over baseline creatinine) occurred in two T&E patients (9.1%), with none requiring permanent
hemodialysis; no significant difference was noted between the two groups (P  .14). One-year mortality and freedom
from reintervention in the T&E patients were 81% and 91%, respectively.
Conclusions:Acceptable short-termmorbidity andmortality can be achieved with T&E compared with TA, despite longer
operative times, greater blood loss, and higher contrast exposure. There was a trend toward higher rates of renal and
spinal cord injury, so implementation of strategies to reduce the potential of these complications or consideration of
staged repair is recommended. Short-term reintervention rates are low, but longer follow-up and greater patient numbers
are needed to determine procedural durability and applicability. ( J Vasc Surg 2012;56:957-64.)
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oAlthough multiple reports have highlighted the safety
and efficacy of endovascular repair of the thoracic (TEVAR)
and infrarenal abdominal (EVAR) aorta,1-6 the application
of these technologies simultaneously in patients harboring
multilevel aortic disease (MLAD) is controversial due to a
theoretical concern for increased morbidity. Synchronous,
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http://dx.doi.org/10.1016/j.jvs.2012.03.272roximal degenerative thoracic aortic pathology is present
n 5% to 13% of patients with abdominal aortic aneurysms,7
nd abdominal aneurysms are present in 10% to 29% of
atients with thoracic aortic aneurysms.8 Descriptions of
atients with mixed aortic pathologies, including aneurysm
long with dissection, penetrating ulcers, complex athero-
atous disease, or postsurgical pseudoaneurysm, have been
eported and further define a unique subset of patients with
LAD.9,10
Noncontinuous aortic pathology in the chest and abdomen
rovides an opportunity for staged management in many pa-
ients. Historically, treatment of these patients has been under-
aken with staged open repair, when possible. However, several
eports have demonstrated the safety of simultaneous repair in
elected patients.11-14 The integration of endoluminal therapies
nto the surgical management of this unique cohort of patients
as resulted in the description of various permutations of staged
r simultaneous hybrid treatment strategies.10,12,15
Another subset of patients with MLAD who warrant
pecific consideration are those with complex type B aortic
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October 2012958 Scali et aldissection (cTBAD). TEVAR has been shown to be safe in
the management of acute and chronic aortic dissec-
tion16,17; however, some patients may have infrarenal aor-
tic aneurysmal degeneration, distal aortic fenestrations, or
secondary entry tears that require management in conjunc-
tion with the proximal entry tear. Staged, nearly total
exclusion of TBAD (acute or chronic) has been reported in
small series,18 but despite these encouraging early results,
the overall reported experience with simultaneous manage-
ment remains largely anecdotal.
Elective simultaneous TEVAR and EVAR (T&E) treat-
ment of patients with MLAD has the potential of increased
morbidity due to increased aortic coverage during a single
surgical encounter, as well as longer operative times, in-
creased blood loss, and greater contrast exposure. Con-
versely, simultaneous T&E provides the benefit of prevent-
ing the need for two operative interventions, potentially
reduces future access site complications, and obviates inter-
val aortic complications that may occur with a staged strat-
egy.11 Our practice at the University of Florida has gener-
ally been to address thoracic and aortic pathologies
concomitantly with simultaneous T&E, when clinically
indicated. With this study, we sought to define our experi-
ence with elective T&E.
METHODS
Database. A dedicated, prospectively maintained en-
dovascular aortic registry is kept at the University of Florida
containing all patients who have undergone endovascular
aortic repair. This database contains 50 patient-specific
and procedure-specific variables that are entered by the
operating surgeon for each patient at the time of the
operation. The database undergoes scheduled quality-
control audits by study coordinators working within the
division. In addition, data within the registry are routinely
updated and augmented by complete review of the medical
record. Any additional data required for this analysis were
obtained by data abstraction from the patient’s electronic
medical record. The University of Florida Institutional
Review Board approved this study.
Patients. All patients who presented to the University
of Florida between January 1, 2001, and July 31, 2011, for
endovascular management of thoracic and aortic pathology
were reviewed. Patients who had documented, combined,
isolated thoracic and abdominal aortic pathology were
identified and further studied. This analysis was intended to
focus on patients with discontinuous MLAD who could be
managed electively (without visceral adjunctive therapies,
such as chimney stents, graft fenestrations or branches, or
visceral debranching) along with patients with cTBAD
undergoing elective T&E. Patients requiring the aforemen-
tioned adjunctive therapies were intentionally excluded
from the analysis, but those who underwent proximal tho-
racic aortic debranching or carotid-to-subclavian bypass
were included. Also excluded were patients with an emer-
gency or urgent indication and mycotic etiologies.
Because no patients were identified who had under-
gone a planned, staged TEVAR and EVAR, T&E patients cere compared with those treated with elective TEVAR
lone (TA) in an attempt to provide comparative procedure-
elated benchmark analysis and safety metrics according to
he Society for Vascular Surgery reporting guidelines.19
lective TA patients were treated for complicated cTBAD
s well as for degenerative aortic pathology, including
escending thoracic aortic aneurysm and nonurgent or
mergency penetrating ulceration. Patients with postsurgi-
al anastomotic pseudoaneurysm, traumatic aortic transec-
ion, coarctation, or any emergency/rupture indication for
A were excluded. Patients who underwent fenestrated
ranched or chimney TEVAR were also excluded from the
tudy population (Supplementary Fig, online only).
All demographic and clinical data were obtained
hrough review of electronic medical records. Preoperative
hin-cut (1- to 2-mm), arterial-phased spiral computed
omography angiography (CTA) scans and operative rec-
rds were reviewed to delineate anatomic pathology, lesion
xtent, location, size, and access-vessel morphology. Oper-
tive records were reviewed to record procedure-
elated variables. Postoperative discharge summaries and
ffice visits were analyzed to capture periprocedural mor-
idity.
Imaging protocol and surveillance. Preoperative
nd postoperative imaging consisted exclusively of CTA.
ortic treatment zones, postoperative endoleak or false
umen perfusion, and graft migration were assessed with
he assistance of three-dimensional reconstruction of axial
maging (TeraRecon Inc, San Mateo, Calif). Postoperative
ortic treatment length for the simultaneous T&E patients
as measured with centerline measurements from the sino-
ubular junction to the aortic bifurcation (total aortic
ength [TAL]) per published reporting standards.19 The
ercentage of aortic coverage was calculated by dividing the
dditive total of the stented aortic segments by TAL (%
ortic coverage  [TEVAR covered  EVAR covered]/
AL 100). The indications for postoperative office visits
r imaging studies were based on a predefined CTA imag-
ng protocol that included delayed venous-phased imaging
t 1, 6, and 12 months, and annually thereafter, unless
adiographic abnormalities, endoleak, or graft integrity dic-
ated otherwise. Reintervention was defined as any second-
ry procedure that was performed to treat the initial in-
ended synchronous aortic pathologies.
Endovascular technique. The endovascular tech-
ique and sequence of graft implantation was left to the
udgment of the operating surgeon, as was the use of spinal
rainage. Postoperative management of the spinal drain
as based on a previously published standardized proto-
ol.20,21 Most frequently, procedural conduct was charac-
erized by TEVAR, followed by EVAR deployment using
tandard device-specific instructions for use. All patients
ndergoing elective repair were systemically heparinized to
chieve an activated clotting time of 250 seconds. Each
urgeon determined the need for preoperative or intraop-
rative adjuncts, such as carotid-to-subclavian bypass or
pen or endovascular access vessel conduit. Technical suc-
ess was defined as successful thoracic and abdominal en-
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Volume 56, Number 4 Scali et al 959dograft deployment into the intended aortic segments,
with angiographic documentation of primary degenerative
pathology exclusion or sluggish flow in the false lumen in
cases of dissection. Intravascular ultrasound imaging was
used universally in dissection patients and selectively in
others.
Postoperative management. All patients treated with
a thoracic endograft at the institution are admitted postop-
eratively to a Thoracic andCardiovascular Surgery intensive
care unit (ICU) for serial neurologic assessment, as well as
monitoring of heart rate and blood pressure. Patients with
a spinal drain were managed using a previously published
protocol.20 Hourly neurologic assessment by ICU staff is
performed in all patients for the initial 48 to 72 hours after
the operation, depending on presence or absence of a spinal
drain and findings of serial neurologic examinations. Any
change in neurologic status prompted further neurologic
examination and imaging as clinically dictated. Volume
resuscitation and vasopressor support, with or without
manipulation of the spinal drain height/drainage volume,
was predicated on the institutional protocol. After recovery
in the Thoracic and Cardiovascular Surgery ICU, patients
were transferred to a dedicated cardiovascular surgery nurs-
ing ward and discharged at the operating surgeon’s discre-
tion.
Data analysis and statistical methods. Peripro-
cedural data, morbidity, and 30-day mortality rates were
analyzed. Postoperative imaging was reviewed for suc-
cessful aneurysm exclusion, size change, and presence of
endoleak. Any deaths were verified through record re-
view and query of the Social Security Death Index.
Statistical analyses were performed using STATA 9.2
software (StataCorp, College Station, Tex). Categoric
factors are summarized using frequencies and percent-
ages, and continuous measure distributions are described
using means  standard deviations and median (range).
Categoric patient characteristics were compared between
groups using the Pearson 2 test or Fisher exact test
when indicated. Continuous measures were compared
using two-sampled t-tests or Wilcoxon rank sum tests, as
appropriate. Kaplan-Meier estimates of survival and re-
intervention were performed. A significance level of 0.05
was assumed for all tests.
RESULTS
From 2000 to 2011, 595 patients underwent TEVAR,
of whom 457 underwent elective repairs. Simultaneous
T&E was used to treat 62 patients, and after those with
emergency indications and those undergoing repair with
fenestrated/branched grafts, chimney stents, or visceral
debranching procedures were excluded, 22 patients (18
men, 82%) were identified who underwent elective T&E
(Supplementary Fig, online only).
Patients were a mean age of 66 9 years (Table I). The
most common comorbidities were hypertension (100%)
and chronic obstructive pulmonary disease (64%). The
median follow-up time was 8.8 months (range, 1-34
months). Four patients (18%) had a history of previous ppen aortic surgery before the index endovascular proce-
ure. The study design and operative indications for the
rocedure included dissection-related pathology in 10
45%), and various combinations of degenerative etiologies
n 12 (55%), including aneurysm, penetrating ulcer, post-
urgical pseudoaneurysm, and atheromatous disease (Fig
). Mean initial aortic diameters for patients whose indica-
ions were not dissection-related were 63.4 17.1mm and
5  10.7 mm in the thoracic and infrarenal aortic seg-
ents, respectively. Of the 10 patients who underwent
&E for dissection-related indications, the mean thoracic
nd abdominal aortic diameters were 56.5  9.9 mm and
5.8  4.4 mm.
A total of 14 preoperative adjunctive procedures were
erformed in 11 patients (50%) and included elephant
runk (n  3), arch debranching (n  5), left carotid-
ubclavian bypass (n  4), hypogastric bypass with con-
omitant iliofemoral bypass (n  1), and renal stent graft
n 1). These procedures occurred at a median of 10 days
range, 1-1805 days) before T&E. Technical success in
&E deployment was 100%. No patients required conver-
ion to open repair. Two patients (9%) had intraprocedural
omplications, both of which were mild to moderate ac-
ording to SVS/Rutherford grading severity22 and related
o access management: one brachial artery thrombosis re-
uiring open thrombectomy, and one iliac dissection ne-
essitating iliac stent placement.
A variety of graft types were used to complete the
horacic and aortic repairs, including thoracic aorta: Cook
X2 (CookMedical Inc, Bloomington, Ind; n 16), Gore
AG (W. L. Gore and Associates, Flagstaff, Ariz; n  5),
X2-TAG (n 1); infrarenal aorta: Zenith (Cook Medical
nc; n  16), Cook Renu (Cook Medical Inc, n  3),
xcluder (W. L. Gore; n 1), Excluder cuff plus Wall graft
Boston Scientific, Natick, Mass; n 1), or Wall graft (n
). Intraoperative technical details regarding TEVAR land-
ng zones and total aortic treatment lengths are further
elineated in Fig 2.
The average number of TEVAR devices used to com-
able I. Patient demographics
Variable N  22
Male, No. (%) 18 (81.8)
Age, mean  SD, years 66  9
Hypertension, % 100
COPD, % 63.6
Dyslipidemia, % 54.5
PVAOD/CVAOD, % 29.2
CAD/myocardial infarction, % 27.0
Prior open aortic operation, % 18.1
Congestive heart failure, % 13.6
CRI (Cr 1.8 mg/dL), % 9.1
Diabetes, % 0
AD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ase; Cr, creatinine; CRI, chronic renal insufficiency; CVAOD, cerebrovas-
ular arterial occlusive disease; PVAOD, peripheral vascular arterial occlusive
isease; SD, standard deviation.lete repair was 2.1  0.8 for all patients (nondissection:
3
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October 2012960 Scali et al1.8 0.8; dissection: 2.3 0.7).With respect to centerline
measured and aortic coverage data for the entire cohort, the
percentage of total aortic stent graft exclusion was 61.3%
15.1% for all patients (nondissection: 56.2%  15.6%;
dissection: 65.6%  13.7%) and total aortic coverage was
Fig 1. Figure demonstrates the various combinations of a
ing simultaneous thoracic endovascular aortic repair (TEVA
inal aortic aneurysm; PAU, penetrating aortic ulcer; TAA,
Fig 2. A, Various landing zones for thoracic endovas
different types of thoracic and aortic stent graft devices
coverage as a function of dissection and aneurysm-rela
deviation.342  88 mm (nondissection: 312  87 mm; dissection: d68 83 mm). The contribution of TEVAR resulted in an
verage treatment length of 226  83 mm for all patients
nondissection: 190 68 mm; dissection: 251 85 mm),
hereas EVAR accounted for an average exclusion mea-
urement of 117 37 mm (nondissection: 118 25 mm;
athologies that were the indications for patients undergo-
d endovascular aneurysm repair (EVAR). AAA, Abdom-
cic aortic aneurysm; TBAD, type B aortic dissection.
aortic repair (TEVAR) are depicted, along with the
to complete the repair. B, The total extent of aortic
dications is shown. The error bars show the standardortic p
R) ancular
used
ted inissection: 117  45 mm).
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Volume 56, Number 4 Scali et al 961A comparative summary for commonly reported
procedural-related details are outlined in Table II. Com-
pared with TA patients, T&E patients had significantly
higher blood loss (P  .0001), contrast exposure (P 
.0001), fluoroscopy time (P  .0001), and operative time
(P  .0001). Preoperative spinal drain placement was re-
quired in 17 T&E patients (77.3%) and in 250 TA patients
(54.7%), which was a significant difference (P  .05). The
rate of any spinal cord ischemia was 13.6% for the T&E
group (n  3) and 6.0% for the TA group (P  .15);
however, the permanent spinal cord ischemia (SCI) rate
was 4% for both groups (P  .96).
The three patients in the T&E group who developed
SCI were treated for degenerative aortic pathology, and
their respective aortic coverage lengths were 41%, 45%, and
78%. All three patients had patent or revascularized aortic
arch vessels. None of these patients had undergone prior
aortic operations. Two of the three patients had patent bilat-
eral internal iliac arteries, whereas one patient (with 41% aortic
coverage) underwent right internal iliac artery embolization
with EVAR extension into the right internal iliac artery (with
a remaining patent left internal iliac artery).
The 30-day mortality was 4.6% for T&E (n  1)
compared with 2.1% for TA (n  10; P  .56), and
in-hospital mortality was 9.1% for T&E (n  2) compared
with 2.5% for TA (n  11; P  .07). A total of 21
Table II. Comparative statistics of commonly reported pe
repair (TEVAR) alone and simultaneous TEVAR and endo
Variableb
TEVAR-EVAR
N  22
Male sex, % 86.4
Age, years 66  9
Preoperative procedure, %d 45.4
Preoperative spinal drain, % 77.3
Estimated blood loss, mL 350 (150-2000)
Contrast, mL 238 (90-420)
Fluoroscopy time, minutes 58 (27-143)
Procedure time, minutes 209 (110-552)
Outcomes
Median LOS (95% CI), days 5 (5-12)
Reintervention at 12
months, %
9.1
Renal injury, %e
Any 9.1
Hemodialysis 0
Spinal chord ischemia, %f
Any 13.6
Permanent 4.5
30-day mortality, % 4.5
CI, Confidence interval; LOS, length of stay; NA, not applicable; OR, odds
aNo significant differences exist between the two patient cohorts with respe
failure, chronic obstructive pulmonary disease, renal insufficiency (preoperat
arterial occlusive disease.
bContinuous variables are shown as mean  standard deviation and mean (
cDetermined using the Fisher exact or t-test, when appropriate.
dIncluded carotid-to-subclavian bypass, embolization, arch debranching, el
eDefined as a change in baseline creatinine of 25%.
fDefined as any decrease in baseline ambulatory ability.complications occurred in nine T&E patients (41%) com- qared with 191 complications in 131 TA patients (28.7%;
 .28). Temporary renal injury (defined by a 25% increase
ver baseline creatinine) occurred in two T&E patients
9.1%), with none requiring permanent hemodialysis; no
ignificant difference was noted between the two groups
P  .14). Other T&E complications (Table III) included
leeding in one patient (4.5%), who required re-
xploration for retroperitoneal bleeding; ischemia in two
9.1%), with one patient requiring left carotid subclavian
ypass 2 weeks postoperatively for arm fatigue, and one
ith lower extremity peripheral embolization who was
anaged expectantly; and gastrointestinal-related compli-
ations in three patients (13.6%), comprising two with
rolonged ileus and one who developed necrotizing pan-
reatitis requiring necrosectomy.
Survival analysis and reintervention. For the T&E
ohort, the overall 12-month survival and 10-month free-
om from reintervention rates were 81% and 91%, respec-
ively (Fig 3). One patient died, for a 30-day mortality of
.5%; however, in-hospital mortality was 9.1% (n 2). One
atient died postoperatively secondary to multiorgan fail-
re (MOF) after developing colon ischemia. The other
atient had a protracted course resulting inMOF after early
postoperative day 2) false lumen rupture (detailed below).
None of the patients with degenerative pathologies
equired reintervention. Three T&E patients (13%) re-
rative outcomes for elective thoracic endovascular aortic
ular aneurysm repair (EVAR)a
TEVAR alone
OR (95% CI) PcN  435
67.0 .4
67  13 .9
23.0 3.4 (1.4-8.0) .004
55.0 2.8 (1-7.8) .04
250 (50-4500) NA .0001
125 (0-305) NA .0001
20 (0-230) NA .0001
100 (37-594) NA .0001
5 (6-7) NA .06
11.0 0.38 (0.2-2.0) .6
3.0 3.5 (0.7-17.0) .1
0.9 Inestimable .99
6.0 2.5 (0.7-9.0) .2
4.4 1.2 (0.2-10.0) .6
2.1 1.8 (0.2-15.0) .4
reoperative comorbidities such as coronary artery disease, congestive heart
atinine1.8 mg/dL), and diabetes mellitus, cerebrovascular, or peripheral
, unless otherwise indicated.
t trunk, or access vessel procedure.riope
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October 2012962 Scali et alwith aneurysmal degeneration and persistent false lumen
perfusion, and they warrant specific discussion. One patient
had persistent false lumen perfusion with aneurysmal de-
generation of the thoracic aorta requiring distal thoracic
endograft extension at 1.4 months postoperatively. Subse-
quent imaging at 3 and 6 months demonstrated a throm-
bosed false lumen with stabilization of aortic diameters.
Another patient received a renal stent graft at 13.1
months after the index procedure for a secondary entry tear,
with continued paravisceral aortic false lumen expansion. This
intervention was initially successful, and follow-up imaging
demonstrated thrombosis of the abdominal portion of the
dissection. The patient subsequently required ascending and
transverse arch replacement at 16.5 months after simultane-
ous T&E due to new development of false lumen perfusion at
the proximal aspect of the graft, with resultant aneurysmal
degeneration of the transverse arch.
The final patient required urgent distal open aortic
replacement 2 days after the index procedure due to false
lumen rupture. MOF developed after that operation, and
the patient died during the postoperative hospitalization
(in-hospital late death; 4.2 months).
Endoleaks. Postoperative imaging noted endoleaks
in three nondissection patients (25%). In one patient a
small type Ia endoleak was noted at 12 months postop-
eratively, without subsequent intervention to date. In
two patients type II endoleaks were noted, one at 2
months and one at 6 months, neither requiring reinter-
vention. Persistent false lumen flow was noted in four
dissection patients (40%), two requiring reintervention
Table III. Postoperative complications in patients
undergoing elective, simultaneous thoracic endovascular
aortic repair (TEVAR) and endovascular aneurysm repair
(EVAR)
Variable
No. (%)
(N  22)
Death
Within 30 days 2 (9.1)
Within hospital stay 1 (4.5)
Spinal cord ischemia
Any 3 (13.6)
Permanent 1 (4.5)
Pulmonary 2 (9.1)
Renal
Any 2 (9.1)
Permanent 1 (4.5)
Gastrointestinal 3 (13.6)
Colon ischemia 1 (4.5)
Pancreatic necrosis 1 (4.5)
Ileus 1 (4.5)
Wound 2 (9.1)
Bleeding requiring pRBC/OR 1 (4.5)
Genitourinary
Urinary tract infection 1 (4.5)
Retention 1 (4.5)
OR, Operation; pRBC, packed red blood cells.as noted above. The other two patients had complete ihrombosis of their false lumen flow on subsequent
ross-sectional imaging.
ISCUSSION
The existing literature has few data to provide clear
ecommendations about the appropriate applicability,
afety, and durability of elective simultaneous endovascular
anagement of synchronous aortic pathology. Our prac-
ice has been to treat both levels of disease in the same
etting when clinically indicated. Consequently, we under-
ook this study to determine our short-term surgical out-
omes of patients treated electivelywithT&E for synchronous
horacic and abdominal aortic disease. This experience, not
nexpectedly, demonstrates that when compared with TA,
imultaneous T&E has longer procedure times, greater
lood loss, and larger amounts of contrast and radiation
xposure. Despite these differences, 30-day mortality, per-
anent paraplegia rates, frequency of renal injury, and
hort-term reintervention rates are comparable in both
neurysm and dissection patients.
Historically, when only open operative techniques were
vailable, high operative mortality and perioperative morbid-
ig 3. A, Kaplan-Meier curves show (A) survival and (B) free-
om from reintervention after elective simultaneous thoracic en-
ovascular aortic repair (TEVAR) and endovascular aneurysm
epair (EVAR). **The dotted lines indicate 10% standard error
ean beyond those intervals.ty of combined thoracotomy and laparotomy led surgeons to
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Volume 56, Number 4 Scali et al 963stage repair in patients with MLAD. The most pressing pa-
thology was treated first, and the second operation was per-
formed after recovery. However, experienced surgeons re-
ported comparable outcomes with a combined approach.
Crawford and Cohen23 reported that of 191 patients with
MLAD treated with combined open thoracic and abdominal
aortic replacement, 90% survived long-term with a combined
repair, and 84% survived when the operations were staged.
When only the symptomatic aneurysm was treated, only 80%
survived long-term. Their most compelling argument for a
single-staged operation was that most of the early postopera-
tive deaths in the staged and isolated symptomatic repair were
secondary to rupture of the untreated aneurysm.
The advent of much less invasive endovascular techniques
has decreased the morbidity and mortality surrounding tho-
racic1,24 and abdominal aortic repair.25,26 Because of the
minimally invasive nature of these procedures, it is tempting to
repair both thoracic and abdominal pathologies concomi-
tantly to prevent futuremorbidity andmortality thatmight be
associated with two separate operations. This is especially true
given that the approach for both procedures is the same
(transfemoral or conduit access) and the procedures can often
be completed in the same setting without much additional
technical complexity.
Despite the minimally invasive nature of TEVAR and
EVAR, there is a known rate of associated major morbidity,
especially with TEVAR. Major complications, including
stroke, SCI, and renal failure, are reported in up to 12% to 17%
of TEVAR patients.9,27 Much lower rates are seen with
EVAR-alone patients, with composite major morbidity rates
of 5% to 7%.27,28 For this reason, and the lack of a true staged
comparison group in our experience, we chose TA patients as
our comparison group in this study.We did not intend this to
be interpreted as a side-by-side comparison of TA vs T&E
outcomes because the groups are too heterogeneous for this
type of analysis. Rather, the description of perioperative out-
comes of TA was only introduced to provide a benchmark of
safety (complications, mortality, and reintervention) and to
highlight the significantly increased procedural complexity
(operative/fluoroscopy times, contrast exposure, blood loss).
Incorporation of this analysis provided the most stringent
endovascular “control group” comparison for short-term
perioperative outcome variables given a lack of available data
on staged EVAR at our institution.
Because of the concern for increased morbidity with si-
multaneous endovascular management of MLAD, many au-
thors have reported staged approaches using various permu-
tations of hybrid and total endovascular techniques. Hybrid
approaches, especially those combining TEVAR with open
abdominal aortic repair, have been reported in an attempt to
obviate the morbidity of thoracotomy.12,29,30 Even when
anatomic and patient-specific variables are optimal, periproce-
dural morbidity and mortality are substantial, with a major
morbidity of 30% to 40% andmortality rate of 8% to 10%.10,11
Possible advantages of a combined approach include ob-
viating the need of a second operation in a high-medical-risk
patient, avoidance of potential future access complications,
and achieving simultaneous management of both aortic pa- phologies, thus reducing risk of interval aortic complications.
arlier notable publications regarding TEVAR and EVAR
ogether include Lucas et al,10 with an experience in 49
atients, 39 of which were classified as havingMLAD. A total
f 21 patientswere treatedwithTEVARandEVAR; however,
nly two patients were truly comparable to our study with
imultaneous thoracic and aortic endografting for patients
ith discontinuous MLAD. Despite these differences with
ur series, encouraging similarities were reported, including a
0-daymortality rate of 4% (6% in-hospital). They reportedno
araplegia events with respect to a multistaged or single-
taged management strategy for complex multilevel aortic
athology. Also of note, the renal injury rate (requiring per-
anent hemodialysis) was 9.5% (n  2) and similar to the
.1% in our experience (n 2).
Further, Kirkwood et al15 reported eight patients who
nderwent simultaneous T&E. Four of these patients were
reated emergently, but nomortality or permanent paraplegia
vents were reported. Only one patient in their series had a
emporary paraparesis, which was resolved with blood pres-
ure augmentation. Their findings further support the feasi-
ility and potential safety of a single-staged treatment strategy
or MLAD.
Our study has several limitations, including the retrospec-
ive nature and the inherent bias that exists because of our
ractice pattern of repairing both levels of disease in a single
etting. Because of this, we do not have a comparable group of
lective, staged T&E patients for analysis. The natural history
f patients with MLAD is poorly defined, so the surgical
ecision-making and eventual outcome of patients treated
edically or surgically cannot be readily derived from this type
f analysis. In addition, because of the mixed aortic patholo-
ies in our patients, it is difficult to provide a true control
roup fromourdata or the existing literature.We included the
wo groups (dissection and degenerative aortic pathology) in
n attempt to understand the effect of procedural complexity
nd aortic coverage length on perioperative safety and out-
ome after simultaneous T&E. Indeed, as we accumulate
ore patients, a more meaningful analysis would be separa-
ion of the two groups.
ONCLUSIONS
Although this represents the largest reported experience
or simultaneous T&E, it is a small sample size with limited
ollow-up. The potential of type II error underscores the
nherent risk of extrapolating these data to general practice
hen considering simultaneous endovascular repair of
LAD. The odds ratio for renal injury for T&E compared
ith TA was 3.5, and although not statistically significant,
here is a 17-fold higher risk of renal injury when comparing
&E with TA patients. Because there was a trend toward
igher SCI, renal injury, and 30-day mortality, practitioners
hould be circumspect before using a combined strategywith-
ut a good clinical indication.
We have shifted our practice toward a staged approach
n the elective setting based on these data. If combined
epair is planned, we recommend measures to decrease the
ossibility of SCI and renal injury, such as preemptive spinal
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October 2012964 Scali et alfluid drainage, and hydration/bicarbonate infusion, as well
as measures to decrease contrast use. Finally, one should
note that the intervening “normal” segment of aorta may
provide an adequate landing zone based on diameter and
existing commercially available devices, but it is clearly at
risk for aneurysmal degeneration in the future, and close
follow-up is recommended.
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